These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37621812)

  • 21. A Critical Review of the Role of the Cannabinoid Compounds Δ
    Jones É; Vlachou S
    Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
    Hardy J; Haywood A; Gogna G; Martin J; Yates P; Greer R; Good P
    Trials; 2020 Jul; 21(1):611. PubMed ID: 32631447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners.
    Miller OS; Elder EJ; Jones KJ; Gidal BE
    Epilepsy Behav; 2022 Feb; 127():108514. PubMed ID: 34998268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial.
    Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG
    JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.
    Kayser RR; Haney M; Raskin M; Arout C; Simpson HB
    Depress Anxiety; 2020 Aug; 37(8):801-811. PubMed ID: 32383271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ
    Peters EN; MacNair L; Mosesova I; Christians U; Sempio C; Klawitter J; Land MH; Ware MA; Turcotte C; Bonn-Miller MO
    Eur J Clin Pharmacol; 2022 Feb; 78(2):259-265. PubMed ID: 34664109
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis.
    Freeman TP; Craft S; Wilson J; Stylianou S; ElSohly M; Di Forti M; Lynskey MT
    Addiction; 2021 May; 116(5):1000-1010. PubMed ID: 33160291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition.
    Colizzi M; Bhattacharyya S
    Curr Addict Rep; 2017; 4(2):62-74. PubMed ID: 28580227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute effects of Δ
    Greenwood LM; Broyd SJ; van Hell HH; Todd J; Jones A; Murray RM; Croft RJ; Michie PT; Solowij N
    Psychopharmacology (Berl); 2022 May; 239(5):1409-1424. PubMed ID: 34719731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comment on Lachenmeier
    Kruse D; Beitzke B
    F1000Res; 2020; 9():900. PubMed ID: 32864108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabis containing equivalent concentrations of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) induces less state anxiety than THC-dominant cannabis.
    Hutten NRPW; Arkell TR; Vinckenbosch F; Schepers J; Kevin RC; Theunissen EL; Kuypers KPC; McGregor IS; Ramaekers JG
    Psychopharmacology (Berl); 2022 Nov; 239(11):3731-3741. PubMed ID: 36227352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Using the BMD Approach to Derive Acceptable Daily Intakes of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) Relevant to Electronic Cigarette Liquids.
    Hindelang P; Scharinger A; Richling E; Walch SG; Lachenmeier DW
    Front Biosci (Landmark Ed); 2022 Jul; 27(8):228. PubMed ID: 36042166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabinoid Content and Label Accuracy of Hemp-Derived Topical Products Available Online and at National Retail Stores.
    Spindle TR; Sholler DJ; Cone EJ; Murphy TP; ElSohly M; Winecker RE; Flegel RR; Bonn-Miller MO; Vandrey R
    JAMA Netw Open; 2022 Jul; 5(7):e2223019. PubMed ID: 35857320
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration.
    Liu Z; Galettis P; Broyd SJ; van Hell H; Greenwood LM; de Krey P; Steigler A; Zhu X; Schneider J; Solowij N; Martin JH
    Intern Med J; 2020 Jul; 50(7):846-853. PubMed ID: 31264294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potency and Therapeutic THC and CBD Ratios: U.S. Cannabis Markets Overshoot.
    Pennypacker SD; Cunnane K; Cash MC; Romero-Sandoval EA
    Front Pharmacol; 2022; 13():921493. PubMed ID: 35734402
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial.
    Dahlgren MK; Lambros AM; Smith RT; Sagar KA; El-Abboud C; Gruber SA
    Commun Med (Lond); 2022 Nov; 2(1):139. PubMed ID: 36352103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for Use of Cannabinoids in Mood Disorders, Anxiety Disorders, and PTSD: A Systematic Review.
    Stanciu CN; Brunette MF; Teja N; Budney AJ
    Psychiatr Serv; 2021 Apr; 72(4):429-436. PubMed ID: 33530732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
    Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
    Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 40. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users.
    Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV
    Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.